All Drug Discovery Processes articles – Page 17
-
ArticleAI meets human tissue to fast-track precision medicine development
By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.
-
ArticleLab of the future: four technologies to watch
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
-
NewsBreakthrough glioblastoma research wins £400k charity funding
King’s College London and Medicines Discovery Catapult have secured £400,000 from The Brain Tumour Charity to fast-track a new drug delivery approach for glioblastoma, the most aggressive brain cancer. The project will support preclinical studies to move potential treatments closer to patients.
-
NewsAI designs new antibiotics to take on drug-resistant superbugs
Penn engineers have built an AI model that creates new antibiotics – and early tests show some work as well as existing approved drugs.
-
ArticleAnimal-free drug discovery is closer with QSP
Quantitative Systems Pharmacology (QSP) is fast becoming a standard tool in drug development, offering a human-relevant way to predict drug effects before the clinic. Dr Josh Apgar of Certara explains how it is helping to cut reliance on animal testing and speed discovery.
-
NewsNew nanostructure makes CRISPR edits safer and three times faster
Northwestern University researchers have created DNA-coated nanoparticles that deliver CRISPR into cells three times more effectively while reducing toxicity. The advance could overcome one of the biggest barriers to gene-editing therapies.
-
NewsThree powerful antibodies discovered with potential to treat mpox
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
-
ArticleInside the search-and-develop model tackling 1,000 untreated skin diseases
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
-
NewsChronic neuron overactivation drives Parkinson’s cell death
New research from Gladstone Institutes shows that chronic overactivation of dopamine-producing neurons can directly trigger their death, offering new insights into why these cells deteriorate in Parkinson’s disease which could lead to potential therapies to slow its progression.
-
NewsNon-invasive method images brain development in juvenile mice
Stanford researchers have developed a non-invasive method to make juvenile mice’s skin transparent, allowing repeated imaging of developing neural circuits. The breakthrough could be used to develop new treatments for neurodevelopmental disorders.
-
NewsNew AI method maps how tuberculosis drugs destroy bacteria
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
-
News
Scientists chart ovarian reserve to help advance new infertility treatments
UCLA scientists have created the first detailed map of how the ovarian reserve forms in primates, offering new insights – and potential new treatments – for infertility, polycystic ovary syndrome (PCOS) and hormone-related conditions.
-
ArticleBeyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 3
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
-
NewsDNA organiser STAG3 could advance infertility and cancer research
Kyoto University researchers have discovered a new DNA-organising protein complex called STAG3-cohesin – a protein that appears in human B cells and blood cancers. This discovery could potentially lead to new approaches for treating infertility and certain cancers.
-
NewsNew M13 virus method could change future genetic treatments
Researchers at the University of Waterloo have developed a modified bacterial virus that can deliver gene therapies cheaper and more efficiently – moving us closer toward personalised, affordable genetic medicine.
-
News
New imaging technique tracks obesity drug tirzepatide in cells
Scientists have developed fluorescent probes that reveal how dual agonist drugs like tirzepatide target cells in the pancreas and brain, offering new insights into diabetes and obesity treatments.
-
ArticleInside the Alzheimer’s study backing stem cells, not drugs
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
-
NewsNew Zika vaccine prevents infection and organ damage
Brazilian researchers have developed a new Zika virus vaccine that is safe and effective in mice – protecting against both brain inflammation and testicular damage while avoiding cross-reactions with dengue.
-
ArticleConsumables engineered for speed and reproducibility in drug discovery
What if familiar lab formats could be redesigned to remove the weak points in permeability and absorbance testing? This article explores how design choices in common consumables can improve both speed and reproducibility in early-stage research.
-
NewsCholesterol drug restores brain barrier function in 22q11.2 syndrome models
Researchers have found that mitochondrial dysfunction in the blood-brain barrier may drive neuropsychiatric disease in 22q11.2 deletion syndrome – and that a cholesterol drug could restore barrier function and ease symptoms.